TaiMed Biologics and AcedrA BioPharmaceuticals partner to commercialize Trogarzo - ZAWYA
| 4147 Stock | TWD 79.90 1.30 1.65% |
Slightly above 53% of TaiMed Biologics' sophisticated investors are presently thinking to get in. The analysis of current outlook of investing in TaiMed Biologics suggests that some traders are interested regarding TaiMed Biologics' prospects. TaiMed Biologics' investing sentiment can be driven by a variety of factors including economic data, TaiMed Biologics' earnings reports, geopolitical events, and overall market trends.
TaiMed Biologics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of TaiMed daily returns and investor perception about the current price of TaiMed Biologics as well as its diversification or hedging effects on your existing portfolios.
TaiMed |
TaiMed Biologics and AcedrA BioPharmaceuticals partner to commercialize Trogarzo ZAWYA
Read at news.google.com
 |
TaiMed Biologics Fundamental Analysis
We analyze TaiMed Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TaiMed Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TaiMed Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Z Score
Z Score Comparative Analysis
TaiMed Biologics is currently under evaluation in z score category among its peers. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
TaiMed Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TaiMed Biologics stock to make a market-neutral strategy. Peer analysis of TaiMed Biologics could also be used in its relative valuation, which is a method of valuing TaiMed Biologics by comparing valuation metrics with similar companies.
Peers
TaiMed Biologics Related Equities
| 4106 | Wellell | 0.20 | ||||
| 4133 | Abnova Taiwan | 0.17 | ||||
| 1734 | Sinphar Pharmaceutical | 0.16 | ||||
| 3164 | GenMont Biotech | 0.50 |
Additional Tools for TaiMed Stock Analysis
When running TaiMed Biologics' price analysis, check to measure TaiMed Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TaiMed Biologics is operating at the current time. Most of TaiMed Biologics' value examination focuses on studying past and present price action to predict the probability of TaiMed Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TaiMed Biologics' price. Additionally, you may evaluate how the addition of TaiMed Biologics to your portfolios can decrease your overall portfolio volatility.